Advanced Accelerator Applications announces Health Canada approval for Lutathera, a treatment for gastro-enteropancreatic neuroendocrine tumours

Advanced Accelerator Applications

7 February 2019 - First ever approved peptide receptor radionuclide therapy in Canada.

Advanced Accelerator Applications today announced that Health Canada has approved Lutathera (lutetium (177Lu) oxodotreotide) for the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastro-enteropancreatic neuroendocrine tumours in adults with progressive disease.

The approval of Lutathera is based on results of the pivotal Phase 3 NETTER-1 study which was published in January 2017 in The New England Journal of Medicine and a single-arm, open-label study conducted by Erasmus Medical Center in Rotterdam, Netherlands.

Read Advanced Accelerator Applications press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada